Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating income | -$2.70M | -$7.63M | -$11.0M | -$13.5M |
| Net income | -$6.71M | -$8.36M | -$10.7M | -$13.2M |
| EPS (diluted) | -$0.85 | -$9.29 | -$8.73 | -$6.64 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$1.20M | -$3.53M | -$7.36M | -$12.6M |
| Capital expenditures | $2.28K | $3.25K | $6.54K | $5.10K |
| Free cash flow | -$1.21M | -$3.53M | -$7.36M | -$12.6M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $32.6K | $8.40M | $10.0M | $4.01M |
| Total assets | $778K | $8.52M | $10.1M | $4.33M |
| Total liabilities | $6.33M | $827K | $2.68M | $1.59M |
| Shareholders' equity | -$5.55M | $7.69M | $7.44M | $2.74M |
| Retained earnings | -$6.71M | -$15.1M | -$25.7M | -$39.0M |
| Shares (wtd avg diluted) | 7.89M | 899K | 1.22M | 1.99M |
Every figure is extracted from Cadrenal Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.